UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $127.67 Million Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 11.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 388,627 shares of the medical research company’s stock after selling 52,471 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 1.39% of Bio-Rad Laboratories worth $127,668,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of BIO. Vanguard Group Inc. boosted its stake in shares of Bio-Rad Laboratories by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 1,919,808 shares of the medical research company’s stock worth $630,676,000 after acquiring an additional 12,168 shares in the last quarter. Wealthfront Advisers LLC acquired a new stake in Bio-Rad Laboratories in the 4th quarter worth approximately $342,686,000. Dimensional Fund Advisors LP boosted its position in Bio-Rad Laboratories by 14.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 746,119 shares of the medical research company’s stock worth $245,106,000 after purchasing an additional 91,690 shares during the period. Earnest Partners LLC boosted its position in Bio-Rad Laboratories by 2.1% during the fourth quarter. Earnest Partners LLC now owns 618,049 shares of the medical research company’s stock worth $203,035,000 after purchasing an additional 12,500 shares during the period. Finally, Ariel Investments LLC grew its holdings in Bio-Rad Laboratories by 48.0% during the fourth quarter. Ariel Investments LLC now owns 560,524 shares of the medical research company’s stock valued at $184,138,000 after purchasing an additional 181,829 shares during the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.

Bio-Rad Laboratories Trading Down 1.3%

Shares of BIO stock opened at $224.08 on Friday. The firm has a market capitalization of $6.10 billion, a P/E ratio of -3.45 and a beta of 1.00. Bio-Rad Laboratories, Inc. has a 1 year low of $215.38 and a 1 year high of $387.99. The firm’s fifty day simple moving average is $241.58 and its 200 day simple moving average is $294.42. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.73 by $0.81. The company had revenue of $585.40 million for the quarter, compared to the consensus estimate of $573.01 million. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. The business’s revenue was down 4.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.30 EPS. As a group, sell-side analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. UBS Group reduced their price objective on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. Citigroup cut their target price on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Royal Bank of Canada decreased their price target on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an “outperform” rating for the company in a report on Friday, May 2nd. Wells Fargo & Company dropped their price objective on Bio-Rad Laboratories from $320.00 to $270.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 17th. Finally, Wall Street Zen cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, Bio-Rad Laboratories has a consensus rating of “Moderate Buy” and an average target price of $327.40.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.